Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OncoVEX GM-CSF plus cisplatin chemoradiation vs cisplatin chemoradiation alone in locally advanced squamous cell carcinoma of the head and neck
2010-019071-29Phase 3Terminated
- Sponsor
- BioVex Group, Inc.
- Start
- Mar 2010
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of talimogene laherparepvec in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by BioVex Group, Inc. Primary endpoint: 2-year event-free survival. Started Mar 2010; status: terminated.
02
Drugs
talimogene laherparepvec
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2010-019071-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019071-29.